Pennsylvania is currently home to 3472 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Assessment of Macrophage Activation syndromE in STill's Disease
NCT06405152
Recruiting
Assessment of Macrophage activation syndrome in STill's disease: retrospective chart analysis of patient History, Symptom resolution and Treatment characteristics
Gender:
All
Ages:
Between 6 months and 80 years
Trial Updated:
05/07/2024
Locations: Swedish Orphan Biovitrum Research Site, Philadelphia, Pennsylvania
Conditions: Macrophage Activation Syndrome, Still's Disease, Adult-Onset, Stills Disease, Juvenile-Onset
Register for Updates
A Study of EDG-7500 in Adult Patients With Obstructive Hypertrophic Cardiomyopathy (CIRRUS-HCM)
NCT06347159
Recruiting
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 either as a single or multiple dose in adult patients with obstructive hypertrophic cardiomyopathy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine), Philadelphia, Pennsylvania
Conditions: Hypertrophic Cardiomyopathy
Register for Updates
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
NCT06299163
Recruiting
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer, Adenocarcinoma of Lung, Triple Negative Breast Cancer, Liposarcoma, Leiomyosarcoma, Mesothelioma, Malignant, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of the Stomach, Melanoma, Malignant, Renal Cell Carcinoma
Register for Updates
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604
Recruiting
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: Paddington Testing Co, Inc., Philadelphia, Pennsylvania
Conditions: Plaque Psoriasis
Register for Updates
MicroRNAs as Biomarkers for Obstructive Sleep Apnea
NCT06189755
Recruiting
Although obstructive sleep apnea (OSA) is a common disorder, there are no blood biomarkers for identification and management of these patients. This project will study microRNAs in order to develop and validate blood biomarkers that are specific to OSA, useful for identification of cases with OSA, reflective of efficacy of therapy, and able to predict blood pressure response to treatment of OSA.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/07/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Obstructive Sleep Apnea
Register for Updates
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296
Recruiting
This phase III trial tests how well adding dinutuximab to induction chemotherapy along with standard of care surgery radiation and stem cell transplantation works for treating children with newly diagnosed high risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found in greater than normal amounts on some types of cancer cells. This helps cells of the immune system kill the cancer cells. Chemotherapy drugs such as cyclophosphamide, topotecan, c... Read More
Gender:
All
Ages:
30 years and below
Trial Updated:
05/07/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Ganglioneuroblastoma, Neuroblastoma
Register for Updates
Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844
Recruiting
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividin... Read More
Gender:
All
Ages:
70 years and above
Trial Updated:
05/07/2024
Locations: Bryn Mawr Hospital, Bryn Mawr, Pennsylvania
Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Register for Updates
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671
Recruiting
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIC to IVA cervical cancer with lymph node involvement) who have not progressed following platinum-based CCRT.
Gender:
Female
Ages:
15 years and above
Trial Updated:
05/07/2024
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Locally Advanced Cervical Cancer
Register for Updates
A Study Using a New Drug, Nivolumab, in Combination With Chemotherapy Drugs to Treat a Type of Cancer Called Nasopharyngeal Carcinoma (NPC)
NCT06064097
Recruiting
This phase II trial tests how well nivolumab in combination with chemotherapy drugs along with radiation therapy works in treating patients with nasopharyngeal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by sto... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
05/07/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
Register for Updates
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638
Recruiting
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a previously implanted dual-chamber Medtronic Astra/Azure DR MRI IPG.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Hypertension, Hypertension, Systolic, Hypertension,Essential
Register for Updates
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
NCT06049797
Recruiting
Hot flashes and night sweats (also known as vasomotor symptoms or VMS) are the most common symptoms which bother women in menopause. This study will follow women going through menopause who have hot flashes and night sweats that cause them bother. They will be starting a non-hormonal therapy prescribed by their healthcare provider (HCP) to treat these symptoms. The women will visit their HCP's office, research center, or both. They will receive prescriptions for the non-hormonal therapy from the... Read More
Gender:
Female
Ages:
Between 40 years and 75 years
Trial Updated:
05/07/2024
Locations: Institute for Female Pelvic Medicine and Reconstructive Surgery, Allentown, Pennsylvania
Conditions: Hot Flashes
Register for Updates
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
NCT06013241
Recruiting
The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/07/2024
Locations: USA015, Hershey, Pennsylvania
Conditions: Chronic Rhinosinusitis Without Nasal Polyps
Register for Updates